---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-216320"
form_type: "8-K"
ticker: "CNTA"
cik: "0001847903"
company_name: "Centessa Pharmaceuticals plc"
filed_at: "2024-09-10T23:59:59+00:00"
generated_at: "2026-05-31T05:42:33.060319+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Centessa ORX750 Phase 1 restores normative wakefulness at 2.5 mg, no hepatotoxicity; Phase 2 in Q4

## Summary
- 2.5 mg dose achieved mean sleep latency of 32 min on MWT vs placebo 17 min (p=0.01), restoring normative wakefulness.
- No hepatotoxicity, visual disturbances, or common OX2R agonist AEs observed; all AEs mild/transient.
- 1.0 mg also statistically significant: mean sleep latency 18 min vs placebo 10 min (p=0.04).
- Plans to initiate Phase 2 studies in narcolepsy NT1, NT2, and idiopathic hypersomnia in Q4 2024.
- Linear PK supports once-daily dosing; systemic exposure dose-proportional.

## SEC filing metadata
- accession: 0001193125-24-216320
- form_type: 8-K
- ticker: CNTA
- cik: 0001847903
- company_name: Centessa Pharmaceuticals plc
- filed_at: 2024-09-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1847903/000119312524216320/0001193125-24-216320-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1847903/000119312524216320/d857057d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-216320
- JSON: https://secwatch.observer/filing/0001193125-24-216320.json
- Plain text: https://secwatch.observer/filing/0001193125-24-216320.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.